Actively Recruiting

Phase 1
Age: 3Years - 25Years
All Genders
NCT06927466

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Led by Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. · Updated on 2025-05-22

33

Participants Needed

8

Research Sites

197 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.

CONDITIONS

Official Title

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Who Can Participate

Age: 3Years - 25Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient or legal guardian agrees to participate and signs informed consent
  • Diagnosed with relapsed or refractory acute B-cell lymphoblastic leukemia
  • Documentation of CD19/CD22 tumor expression
  • Liver, kidney, lung, and heart functions meet study requirements
  • Expected survival longer than 3 months
  • Women of childbearing age and all post-adolescent males agree to use effective contraception for 1 year after B019 infusion and not donate eggs or sperm for assisted reproduction during that time
Not Eligible

You will not qualify if you...

  • Active central nervous system involvement by cancer
  • Isolated extramedullary leukemia recurrence
  • Grade 2 or higher acute or moderate to severe chronic graft-versus-host disease within 4 weeks before screening
  • Prior treatment with CAR-T therapy or other treatments abandoned in protocol
  • Received protocol-abandoned therapy before PBMC collection or B019 injection
  • Active other malignancies within the past 5 years
  • Positive for any of HBsAg, HBeAg, HBeAb, HBcAb, HCV-RNA, HIV, EBV DNA, CMV DNA, HTLV antibodies
  • Any other condition deemed unsuitable for participation by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

Peking University People's Hospital

Beijing, China

Actively Recruiting

2

Jiangxi Province pediatric hospital

Nanchang, China

Actively Recruiting

3

The First Affiliated Hospital of Nanchang University

Nanchang, China

Actively Recruiting

4

Children's Hospital of Shanghai

Shanghai, China

Actively Recruiting

5

Shanghai Children's Medical Center

Shanghai, China

Actively Recruiting

6

Children's Hospital of Soochow University

Suzhou, China

Actively Recruiting

7

Tongji Hospital

Wuhan, China

Actively Recruiting

8

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, China

Actively Recruiting

Loading map...

Research Team

J

Jing Chen

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here